Information on EC 3.4.11.3 - cystinyl aminopeptidase

for references in articles please use BRENDA:EC3.4.11.3
Word Map on EC 3.4.11.3
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Specify your search results
Select one or more organisms in this record:
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)


The expected taxonomic range for this enzyme is: Eukaryota, Bacteria

top print hide
EC NUMBER
COMMENTARY hide
3.4.11.3
-
top print hide
RECOMMENDED NAME
GeneOntology No.
cystinyl aminopeptidase
-
top print hide
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
Release of an N-terminal amino acid, Cys-/-Xaa-, in which the half-cystine residue is involved in a disulfide loop, notably in oxytocin or vasopressin. Hydrolysis rates on a range of aminoacyl arylamides exceed that for the cystinyl derivative, however
show the reaction diagram
-
-
-
-
top print hide
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Aminoacylation
-
-
hydrolysis of peptide bond
-
-
exopeptidase, N-terminus amino acid
-
top
top print hide
CAS REGISTRY NUMBER
COMMENTARY hide
9031-41-8
-
top print hide
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
Manually annotated by BRENDA team
monkey
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
-
-
-
Manually annotated by BRENDA team
top print hide
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
inhibition of central enzyme activity by injection of amastatin in anaesthetised suckling mothers increases the frequency of reflex milk ejections
physiological function
-
part of the AT4 receptor
top print hide
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
alpha-L-Asp1-Val5-angiotensin II + H2O
beta-Asp1-Val5-angiotensin II
show the reaction diagram
-
transformation to beta form
-
ir
angiotensin III + H2O
?
show the reaction diagram
Arg-4-methylcoumaryl-7-amide + H2O
Arg + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
Arg-4-nitroanilide + H2O
Arg + 4-nitroaniline
show the reaction diagram
-
-
-
?
arginine vasopressin + H2O
?
show the reaction diagram
-
-
-
-
?
Cys-4-nitroanilide + H2O
Cys + 4-nitroaniline
show the reaction diagram
L-Ala-2-naphthylamide + H2O
L-Ala + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-alanine-p-nitroanilide + H2O
L-alanine + p-nitroaniline
show the reaction diagram
L-Arg-vasopressin + H2O
L-Arg + vasopressin
show the reaction diagram
-
-
-
-
?
L-benzyl-L-Cys-2-naphthylamide + H2O
L-benzyl-L-Cys + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-benzyl-L-cysteine-p-nitroanilide + H2O
L-benzyl-L-cysteine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
L-cystine di-beta-naphthylamide + H2O
?
show the reaction diagram
L-cystine-di-p-nitroanilide + H2O
L-cystine + p-nitroaniline
show the reaction diagram
L-Leu-2-naphthylamide + H2O
2-naphthylamine + L-Leu
show the reaction diagram
-
-
-
-
?
L-Leu-2-naphthylamide + H2O
L-Leu + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-Leu-4-nitroanilide + H2O
L-Leu + 4-nitroaniline
show the reaction diagram
L-Leu-enkephalin + H2O
L-Leu + enkephalin
show the reaction diagram
-
-
-
-
?
L-Leu-p-nitroanilide + H2O
L-Leu + p-nitroaniline
show the reaction diagram
-
-
-
-
?
L-leucine-7-amido-4-methylcoumarin + H2O
L-leucine + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
L-leucine-p-nitroanilide + H2O
L-leucine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
L-Lys-2-naphthylamide + H2O
L-Lys + 2-naphthylamine
show the reaction diagram
-
-
-
-
?
L-lysine-p-nitroanilide + H2O
L-lysine + p-nitroaniline
show the reaction diagram
L-methionine-p-nitroanilide + H2O
L-methionine + p-nitroaniline
show the reaction diagram
-
-
-
-
?
Leu-4-methylcoumaryl-7-amide + H2O
Leu + 7-amino-4-methylcoumarin
show the reaction diagram
Leu-4-nitroanilide + H2O
Leu + 4-nitroaniline
show the reaction diagram
-
-
-
?
Lys-4-methylcoumaryl-7-amide + H2O
Lys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
Met-4-methylcoumaryl-7-amide + H2O
Met + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
oxytocin + H2O
?
show the reaction diagram
oxytocin + H2O
acyclic peptide + H2O
show the reaction diagram
Peptides + H2O
?
show the reaction diagram
-
enzyme plays a role in general metabolism of peptides during pregnancy
-
-
-
S-benzyl-Cys-4-methylcoumaryl-7-amide + H2O
S-benzyl-Cys + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
?
S-benzyl-cysteine-4-methylcoumarin 7-amide + H2O
S-benzyl-cysteine + 7-amino-4-methylcoumarin
show the reaction diagram
-
-
-
-
?
S-benzyl-L-cysteine-p-nitroanilide + H2O
S-benzyl-L-cysteine + p-nitroaniline
show the reaction diagram
somatostatin + H2O
?
show the reaction diagram
-
-
-
-
?
Vasopressin + H2O
?
show the reaction diagram
vasopressin + H2O
hydrolyzed vasopressin
show the reaction diagram
additional information
?
-
top print hide
NATURAL SUBSTRATES
NATURAL PRODUCTS
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
angiotensin III + H2O
?
show the reaction diagram
oxytocin + H2O
?
show the reaction diagram
Peptides + H2O
?
show the reaction diagram
-
enzyme plays a role in general metabolism of peptides during pregnancy
-
-
-
Vasopressin + H2O
?
show the reaction diagram
vasopressin + H2O
hydrolyzed vasopressin
show the reaction diagram
-
vasopressin is a physiological substrate
N-terminal processing
-
?
additional information
?
-
top print hide
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Cl-
-
stimulation
Cu2+
-
partly reverses EDTA inhibition
Mg2+
-
inhibitory effect of EDTA plus 1,10-phenanthroline can be completely reversed by Zn2+. Ca2+ and Mg2+ increase the potency of Zn2+ for this process
Ni2+
-
stimulation, reverses EDTA inhibition
top print hide
INHIBITORS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
(2-[[(N-[[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
1,10-phenanthroline
1,16-bis(4-methyl-2,5-dioxo-3-furyl)hexadecane
-
tyromycin A
1,2-Acyclic oxytocin
-
slight inhibition of oxytocin degradation, marked inhibition of cystine di-beta-naphthylamide degradation
1-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-6-sulfonamide
-
-
2,2'-bipyridine
-
acetic acid-containing chelators potentiate the inhibitory effect of 2,2'-bipyridine. Efficiacy decreases in the order: diethylenetriamine-N,N,N',N'',N''-pentaacetic acid, EDTA, EGTA
2,2'-dipyridyl
-
-
2,4,5-trichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
-
2-amino-4-(3,5-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
-
2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(3-methoxyphenyl)-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(4-methoxyphenyl)-4H-chromene-3-carbonitrile
-
-
2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carbonitrile
-
-
2-mercaptoethanol
2-methoxyethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]benzoic acid
-
-
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
3,4-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
3,4-dimethyl-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
3-([(4-bromo-5-chlorothiophen-2-yl)sulfonyl]amino)-N-methylbenzamide
-
-
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-amino-3-(L-arginylamino)benzoic acid
-
4-amino-3-(L-tyrosylamino)benzoic acid
-
4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoic acid
-
4-bromo-2,6-difluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
4-bromo-2-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide
-
-
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-1,3-dihydro-2,1,3-benzoxadiazole-4-sulfonamide
-
-
8-bromo-cGMP
-
-
8-hydroxyquinoline
-
-
amastatin
Ang II
-
-
Ang IV
-
-
angiotensin
-
-
angiotensin 4-8
angiotensin II
angiotensin II(5-8)
-
-
Angiotensin III
angiotensin IV
aprotonin
-
-
-
benzyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
-
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valinate
-
benzyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
-
benzyl N-[3-amino-4-(L-leucylamino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valinate
-
benzyl N-[3-amino-4-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-tryptophanate
-
benzyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valinate
-
benzyl N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophanate
-
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valinate
-
benzyl N-[4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
-
bestatin
butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
Ca2+
-
slightly
cGMP
-
-
Cloxacillin
-
-
CuCl2
-
0.1 mM, 91% inhibition. 0.01 mM, 87% inhibition
cyclohexylmethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
cysteine
diethylenetriamine-N,N,N',N'',N''-pentaacetic acid
-
weak
divalinal
divalinal-angiotensin IV
-
-
ethyl 2,7-diamino-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-(acetylamino)-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-(acetylamino)-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(2,4-dichloropyridin-3-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(2-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(3-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(3-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(4-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(4-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(5,8-dihydroquinolin-2-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[g]chromene-3-carboxylate
-
-
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[h]chromene-3-carboxylate
-
-
ethyl 2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-6-bromo-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-6-chloro-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-(dimethylamino)-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-(formyloxy)-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-(1,3-thiazol-2-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-(2-nitrophenyl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(4-methylphenyl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(4-nitrophenyl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(pyridin-2-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(quinolin-4-yl)-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-(thiophen-2-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-hydroxy-4-[4-(pyridin-2-yl)phenyl]-4H-chromene-3-carboxylate
-
-
ethyl 2-amino-7-methoxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
50% inhibition at 100 microM
ethyl 2-amino-8-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
Fe2+
-
-
HCO3-
-
-
indomethacin
-
-
iodoacetic acid
L-Arg-vasopressin
-
Ki-value for wild-type, mutants G428E, G428D, G428Q above 0.03 mM
L-Leu-enkephalin
-
-
L-leucine
-
-
L-methionine
-
form I inhibited, form II slightly activated
L-phenylalanine
-
-
L-trans-epoxysuccinyl-leucinamido(4-guanidino)-butane
-
E64
L-tyrosine
-
-
L-Val-L-Tyr-L-Ile-2-aminomethylphenylacetic acid
-
inhibits both IRAP and aminopeptidase N and induces proliferation of stem cells at low concentrations
L-Val-L-Tyr-L-Ile-L-Cys-L-Pro-L-Cys
-
cyclic disulfide, angiotensin IV analog, considerably more stable than angiotensin IV toward enzymatic degradation
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-cyclohexylalanine
-
-
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe
Leu-Val-Val-haemorphin 7
-
-
leupeptin
-
0.1 mM, 53% inhibition
LVV-H7
LVV-haemorphin-7
-
-
LVV-hemorphin 7
methyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
methyl 3-amino-4-(L-arginylamino)benzoate
-
methyl 3-amino-4-(L-norleucylamino)benzoate
-
methyl 3-amino-4-(L-tyrosylamino)benzoate
-
methyl 3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoate
-
methyl 3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoate
-
methyl 4-amino-3-(L-arginylamino)benzoate
-
methyl 4-amino-3-(L-norleucylamino)benzoate
-
methyl 4-amino-3-(L-tyrosylamino)benzoate
-
methyl 4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoate
-
methyl 4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoate
-
methyl 4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoate
-
methyl N-(3,4-diaminobenzoyl)-L-tyrosinate
-
methyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
-
methyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
-
methyl N-[3-amino-4-(L-arginylamino)benzoyl]-L-tyrosinate
-
methyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tyrosinate
-
methyl N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tyrosinate
-
methyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tyrosinate
-
methyl N-[4-amino-3-(D-norleucylamino)benzoyl]-D-tyrosinate
-
methyl N-[4-amino-3-(L-arginylamino)benzoyl]-D-tyrosinate
-
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-threoninate
-
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tyrosinate
-
methyl N2-(3,4-diaminobenzoyl)-L-argininate
-
methyl N2-(3,4-diaminobenzoyl)-L-lysinate
-
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-argininate
-
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-(4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
-
methyl N2-[3-amino-4-(L-arginylamino)benzoyl]-L-lysinate
-
methyl N2-[3-amino-4-(L-leucylamino)benzoyl]-L-lysinate
-
methyl N2-[3-amino-4-(L-norleucylamino)benzoyl]-L-lysinate
-
methyl N2-[3-amino-4-(L-tyrosylamino)benzoyl]-L-lysinate
-
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-D-argininate
-
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-L-lysinate
-
methyl N2-[4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-lysinate
-
N-(3,4-diaminobenzoyl)-L-tryptophan
-
N-(3-amino-4-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
-
N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valine
-
N-(4-amino-3-[[(2R)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
-
N-alpha-tosyl-L-lysylchloromethane
-
-
N-ethylmaleimide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]-2-benzothiophene-4-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]biphenyl-4-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]pyridine-3-sulfonamide
-
-
N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
-
-
N-[3-amino-4-(L-arginylamino)benzoyl]-L-tryptophan
-
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophan
-
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valine
-
N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valine
-
N-[4-amino-3-(L-arginylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(L-arginylamino)benzoyl]-L-valine
-
N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophan
-
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valine
-
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucine
-
-
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine
-
-
N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-ornithine
-
N2-[4-amino-3-(L-leucylamino)benzoyl]-L-lysine
-
N2-[4-amino-3-(L-phenylalanylamino)benzoyl]-L-lysine
-
N2-[4-amino-3-(L-tyrosylamino)benzoyl]-L-lysine
-
NaCN
-
-
p-chloromercuribenzoate
p-hydroxymercuribenzoate
-
-
pepstatin A
-
0.1 mM, 70% inhibition
Polyphloretin phosphate
-
-
porcine ACTH(1-39)
-
-
-
propyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
prostaglandin E-1
prostaglandin E2
prostaglandin F-2alpha
puromycin
-
0.1 mM, 36% inhibition. 0.01 mM, 5% inhibition
S-Benzyl-L-cysteinyl-L-prolyl-L-leucyl-glycinamide
-
-
S-benzylcysteine
-
and S-benzylcysteine containing peptides
Somatostatin
-
-
tert-butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
-
tosylphenylalanine-chloromethane
-
-
Urea
-
-
ZnCl2
-
0.1 mM, 98% inhibition. 0.01 mM, 77% inhibition
[2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromen-3-yl](phenyl)methanone
-
50% inhibition at 100 microM
[2-[([[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
[2-[([[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
additional information
-
top print hide
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
2-mercaptoethanol
glutathione
-
stimulates
top print hide
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.529
Arg-4-nitroanilide
-
pH 7.4, 37°C, wild-type enzyme
0.022
arginine-4-methylcoumarin 7-amide
-
-
0.331
Cys-4-nitroanilide
-
pH 7.4, 37°C, wild-type enzyme
0.5
L-Ala-2-naphthylamide
-
-
1.43
L-alanine-p-nitroanilide
-
-
0.046
L-Arg-beta-naphthylamide
-
-
0.0225
L-cysteine-nitroanilide
-
-
0.045 - 0.59
L-Leu-2-naphthylamide
0.25
L-Leu-4-nitroanilide
-
pH 7.4, 37°C
0.15 - 0.867
L-leucine-p-nitroanilide
0.43 - 3
L-Lysine-p-nitroanilide
0.83
L-methionine-p-nitroanilide
-
-
0.029
L-Trp-beta-naphthylamide
-
-
0.0225
Leu-4-methylcoumaryl-7-amide
-
pH 7.5, 37°C
0.243 - 0.9148
Leu-4-nitroanilide
0.36
leucyl-p-nitroanilide
-
pH 7.4
0.0107
lysine-vasopressin
-
-
0.0051
Oxytocin
-
-
0.11
phenylalanine-4-methylcoumarin 7-amide
-
-
-
0.0436
S-benzyl-Cys-4-methylcoumaryl-7-amide
-
pH 7.5, 37°C
0.006
S-benzyl-cysteine-4-methylcoumarin 7-amide
-
-
0.0056 - 0.45
S-benzyl-L-cysteine-p-nitroanilide
0.0017
Vasopressin
-
-
additional information
additional information
-
top print hide
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.04 - 9.18
Leu-4-methylcoumaryl-7-amide
12.4
S-benzyl-Cys-4-methylcoumaryl-7-amide
-
pH 7.5, 37°C
top print hide
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0033
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
0.0074
(2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]phenyl)acetic acid
-
-
0.0014
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
0.0039
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]phenyl)acetic acid
-
-
0.0013
(2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
97
(2-[[(N-[[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]-L-isoleucyl)amino]methyl]phenyl)acetic acid
-
-
0.05
2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
pH 7.4, 37°C
0.1
2-amino-4-(3,5-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(3,4,5-trimethoxyphenyl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(3-methoxyphenyl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(4-methoxyphenyl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.1
2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carbonitrile
-
value above, pH 7.4, 37°C
0.004
2-methoxyethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0063
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
0.012
2-[[(1-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-prolyl)amino]methyl]benzoic acid
-
-
0.0018
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
0.0037
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-norleucylamino)phenyl]carbonyl]-L-leucyl)amino]methyl]benzoic acid
-
-
0.0013
2-[[(N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl)amino]methyl]benzoic acid
-
-
0.0014
amastatin
-
pH 7.5, 37°C
0.00006
angiotensin IV
-
in 50 mM Tris-HCl (pH 7.4), 140 mM NaCl, 0.1% (w/v) bovine serum albumin, and 0.1 mM phenylmethylsulfonyl fluoride, at 37°C
0.0017
benzyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0026
butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.00048
ethyl 2-(acetylamino)-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.00003
ethyl 2-(acetylamino)-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.014
ethyl 2-amino-4-(2,4-dichloropyridin-3-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-4-(2-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0062
ethyl 2-amino-4-(3,4-dimethoxyphenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.035
ethyl 2-amino-4-(3-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0032
ethyl 2-amino-4-(3-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-4-(4-bromophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.1
ethyl 2-amino-4-(4-chlorophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.011
ethyl 2-amino-4-(4-cyanophenyl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.003
ethyl 2-amino-4-(5,8-dihydroquinolin-2-yl)-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[g]chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.1
ethyl 2-amino-4-(pyridin-3-yl)-4H-benzo[h]chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0053
ethyl 2-amino-4-[4-(dimethylamino)phenyl]-7-hydroxy-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0056
ethyl 2-amino-6-chloro-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.042
ethyl 2-amino-7-hydroxy-4-(2-nitrophenyl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-7-hydroxy-4-(4-methylphenyl)-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0077
ethyl 2-amino-7-hydroxy-4-(4-nitrophenyl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0029
ethyl 2-amino-7-hydroxy-4-(pyridin-2-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0018
ethyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0037
ethyl 2-amino-7-hydroxy-4-(pyridin-4-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.00036
ethyl 2-amino-7-hydroxy-4-(quinolin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0009
ethyl 2-amino-7-hydroxy-4-(quinolin-4-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.1
ethyl 2-amino-7-hydroxy-4-phenyl-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.1
ethyl 2-amino-7-hydroxy-4-[4-(pyridin-2-yl)phenyl]-4H-chromene-3-carboxylate
-
value above, pH 7.4, 37°C
0.0098
ethyl 2-amino-8-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.003 - 0.016
L-Arg-vasopressin
0.335 - 3.17
L-Leu-enkephalin
0.0000019
L-Val-L-Tyr-L-Ile-2-aminomethylphenylacetic acid
-
pH 7.4, 37°C
0.0000065
L-Val-L-Tyr-L-Ile-L-Cys-L-Pro-L-Cys
-
pH 7.4, 37°C
0.0000079
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-cyclohexylalanine
-
pH 7.4, 37°C
0.0000046
L-Val-L-Tyr-L-Ile-L-His-L-Pro-L-Phe
-
pH 7.4, 37°C
0.0049
methyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
76
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucine
-
-
0.0012
N-[[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanine
-
-
0.0016
propyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
0.0119
tert-butyl 2-amino-7-hydroxy-4-(pyridin-3-yl)-4H-chromene-3-carboxylate
-
pH 7.4, 37°C
16
[2-[([[3-(4-hydroxybenzyl)-5-(L-valylamino)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
35
[2-[([[3-amino-5-(4-hydroxybenzyl)phenyl]carbonyl]amino)methyl]phenyl]acetic acid
-
-
top print hide
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.2
1,10-phenanthroline
Cricetulus griseus;
-
IC50: 0.2 mM. Inhibitory effect is substantially potentiated by both EDTA and EGTA. A combined and complete inhibition of the enzyme activity by 0.1 mM EDTA and 0.1 mM 1,10-phenanthroline can be prevented in the presence of 0.04-0.1 mM ZnCl2
0.022
1-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]-1H-indole-6-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0029
2,4,5-trichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0011
3,4-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0031
3,4-dimethyl-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.125
3-([(4-bromo-5-chlorothiophen-2-yl)sulfonyl]amino)-N-methylbenzamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0018
4,5-dichloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.034
4-amino-3-(L-arginylamino)benzoic acid
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.01
4-amino-3-(L-tyrosylamino)benzoic acid
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.01
4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoic acid
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0079
4-bromo-2,6-difluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0016
4-bromo-2-fluoro-N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.058
4-bromo-5-chloro-N-methyl-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.125
4-bromo-5-chloro-N-[3-(1-methyl-1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.067
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-carboxamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0021
4-bromo-5-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0013
7-chloro-N-[3-(1H-tetrazol-5-yl)phenyl]-1,3-dihydro-2,1,3-benzoxadiazole-4-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.00072
angiotensin IV
Cricetulus griseus;
-
IC50: 0.00072 mM
0.0024
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.014
benzyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0013
benzyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0037
benzyl N-[3-amino-4-(L-leucylamino)benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.000438
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0039
benzyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0034
benzyl N-[3-amino-4-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0038
benzyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.001
benzyl N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.000105
benzyl N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0071
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.012
benzyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.000933
benzyl N-[4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tryptophanate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0396
methyl 3-amino-4-(L-arginylamino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0033
methyl 3-amino-4-(L-norleucylamino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0083
methyl 3-amino-4-(L-tyrosylamino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0017
methyl 3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.031
methyl 3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.014
methyl 4-amino-3-(L-arginylamino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0072
methyl 4-amino-3-(L-norleucylamino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.057
methyl 4-amino-3-(L-tyrosylamino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0021
methyl 4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.01
methyl 4-amino-3-[(O-benzyl-L-tyrosyl)amino]benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.012
methyl 4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0099 - 0.022
methyl N-(3,4-diaminobenzoyl)-L-tyrosinate
0.0013
methyl N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0036
methyl N-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0022
methyl N-[3-amino-4-(L-arginylamino)benzoyl]-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0036
methyl N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0037
methyl N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0029
methyl N-[3-amino-4-[(O-benzyl-L-tyrosyl)amino]benzoyl]-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0012
methyl N-[4-amino-3-(D-norleucylamino)benzoyl]-D-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.000966
methyl N-[4-amino-3-(L-arginylamino)benzoyl]-D-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-threoninate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.022
methyl N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tyrosinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0025
methyl N2-(3,4-diaminobenzoyl)-L-argininate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
methyl N2-(3,4-diaminobenzoyl)-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0047
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-argininate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.02
methyl N2-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0107
methyl N2-(4-amino-3-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.01
methyl N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0049
methyl N2-[3-amino-4-(L-arginylamino)benzoyl]-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
methyl N2-[3-amino-4-(L-leucylamino)benzoyl]-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0357
methyl N2-[3-amino-4-(L-norleucylamino)benzoyl]-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.07
methyl N2-[3-amino-4-(L-tyrosylamino)benzoyl]-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.031
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-D-argininate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
methyl N2-[4-amino-3-(L-norleucylamino)benzoyl]-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0057
methyl N2-[4-amino-3-([(2S)-2-amino-4-[4-(benzyloxy)phenyl]butanoyl]amino)benzoyl]-L-lysinate
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
N-(3,4-diaminobenzoyl)-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0052
N-(3-amino-4-[[(2S)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.02
N-(3-amino-4-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-valine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0044
N-(4-amino-3-[[(2R)-2-amino-4-(4-hydroxyphenyl)butanoyl]amino]benzoyl)-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.016
N-[3-(1H-tetrazol-5-yl)phenyl]-1-benzothiophene-2-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.039
N-[3-(1H-tetrazol-5-yl)phenyl]-2-benzothiophene-4-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.125
N-[3-(1H-tetrazol-5-yl)phenyl]benzenesulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.044
N-[3-(1H-tetrazol-5-yl)phenyl]biphenyl-4-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.125
N-[3-(1H-tetrazol-5-yl)phenyl]pyridine-3-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.125
N-[3-(1H-tetrazol-5-yl)phenyl]thiophene-2-sulfonamide
Cricetulus griseus;
-
pH 7.4, temperature not specified in the publication
0.0076
N-[3-amino-4-(L-arginylamino)benzoyl]-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0017
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
N-[3-amino-4-(L-norleucylamino)benzoyl]-L-valine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0013
N-[3-amino-4-(L-tyrosylamino)benzoyl]-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
N-[4-amino-3-(D-norleucylamino)benzoyl]-L-valine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.000655
N-[4-amino-3-(L-arginylamino)benzoyl]-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0033
N-[4-amino-3-(L-arginylamino)benzoyl]-L-valine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.000296
N-[4-amino-3-(L-norleucylamino)benzoyl]-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-tryptophan
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
N-[4-amino-3-(L-tyrosylamino)benzoyl]-L-valine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.1
N2-(4-amino-3-[[(2S)-2-amino-4-phenylbutanoyl]amino]benzoyl)-L-ornithine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0041
N2-[4-amino-3-(L-leucylamino)benzoyl]-L-lysine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0038
N2-[4-amino-3-(L-phenylalanylamino)benzoyl]-L-lysine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
0.0048
N2-[4-amino-3-(L-tyrosylamino)benzoyl]-L-lysine
Homo sapiens;
Q9UIQ6
pH and temperature not specified in the publication
top print hide
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
4.35
-
-
additional information
-
-
top print hide
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
6.8
-
S-benzyl-L-cysteine-p-nitroanilide, SP I
6.8 - 8
-
CAP-II
7
-
S-benzyl-L-cysteine-p-nitroanilide, SP II
7 - 7.7
-
depending on substrate
7.2
-
L-leucine-p-nitroanilide, SP I
7.4 - 8
-
CAP-I
7.8
-
-
top print hide
pH RANGE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7 - 8
-
pH 7.0: about 15% of activity maximum, pH 8.0: about 10% of activity maximum
top print hide
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
30
-
assay at
top print hide
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
-
trophoblastic cell. Insulin induces enzyme expression in trophoblasts
Manually annotated by BRENDA team
-
clear cell renal carcinoma cell
Manually annotated by BRENDA team
-
chromophobe renal carcinoma cell
Manually annotated by BRENDA team
-
P-LAP is detected in all clear-cell adenocarcinomas
Manually annotated by BRENDA team
-
high activity
Manually annotated by BRENDA team
-
P-LAP is detected in 2 of 11 benign cystadenomas
Manually annotated by BRENDA team
-
P-LAP is detected in 15 of 17 endometrioid adenocarcinomas
Manually annotated by BRENDA team
-
of hepato-biliary
Manually annotated by BRENDA team
-
high activity in the inner mucosal lining of the ampulla segment of the Fallopian tube, lower level in the interstitial and isthmus
Manually annotated by BRENDA team
-
highest concentration in the outer myometrial layer of the uterus, lower levels in the inner myometrial layer and in the luminal epithelium
Manually annotated by BRENDA team
-
enzyme in soluble fraction, no activity detected in particulate fraction
Manually annotated by BRENDA team
-
P-LAP is located in the periphery in early gestation, located in both the periphery and inner cells during mid-gestation, located only in inner cells in late gestation
Manually annotated by BRENDA team
-
Madin-Darby bovine kidney cell
Manually annotated by BRENDA team
-
P-LAP is detected in 13 of 14 mucinous adenocarcinomas
Manually annotated by BRENDA team
-
P-LAP is detected in 7 of 14 borderline tumors
Manually annotated by BRENDA team
-
expression of the enzyme is increased during the differentiation of the cells into neuronal cells
Manually annotated by BRENDA team
-
papillary renal carcinoma cell
Manually annotated by BRENDA team
-
cystinyl aminopeptidase is 100% higher in the left than in the right prefrontal cortex
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
-
tendency towards increased P-LAP expression with advancing grade is observed in serous adenocarcinomas
Manually annotated by BRENDA team
-
modest expression
Manually annotated by BRENDA team
-
-
Manually annotated by BRENDA team
additional information
-
no activity in soluble and particulate fraction of midbrain and hypophysis
Manually annotated by BRENDA team
top print hide
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
-
the enzyme translocates to the cell surface within GLUT4 vesicles in response to insulin
Manually annotated by BRENDA team
-
P-LAP is translocated from the cytosol to the plasma membrane by oxytocin stimulation in vascular endothelial cells and by vasopressin in renal cells
Manually annotated by BRENDA team
-
insulin-stimulated translocation of IRAP remains intact despite substantial knock-down of glucose transporter GLUT4. By contrast, insulin-stimulated GLUT4 translocation is impaired upon IRAP knock-down. Tankyrase knock-down alters the basal partitioning of GLUT4 and IRAP within endosomal compartments
Manually annotated by BRENDA team
-
defects in the intracellular trafficking of P-LAP/IRAP-containing GLUT4 vesicle are associated with type 2 diabetes
-
Manually annotated by BRENDA team
-
low activity
Manually annotated by BRENDA team
top print hide
PDB
SCOP
CATH
UNIPROT
ORGANISM
Homo sapiens;
top print hide
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
24000
-
isoenzyme I, x * 24000, SDS-PAGE
30000
-
x * 30000, SDS-PAGE
40000
-
1 * 56000 + 1 * 40000, SDS-PAGE
50000
-
6 * 50000, SDS-PAGE
52000
-
non-denaturing PAGE
56000
-
1 * 56000 + 1 * 40000, SDS-PAGE
61000
-
CAP-I, 1 * 61000, SDS-PAGE
64000
-
CAP-I, gel filtration
66000
-
gel filtration, SDS-PAGE
76400
-
enzyme II, gel filtration
87000
-
gel filtration
97000
-
CAP-II, gel filtratrion
103000
-
1 * 103000, SDS-PAGE
104000
-
1 * 104000, SDS-PAGE
105000
-
gel filtration
106000
-
gel filtration
140000
170000
-
2 * 170000, SDS-PAGE
280000
300000
309000
-
enzyme I, gel filtration
340000
-
gel filtration
top print hide
SUBUNITS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
isoenzyme I, x * 24000, SDS-PAGE; x * 30000, SDS-PAGE
hexamer
-
6 * 50000, SDS-PAGE
monomer
top print hide
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
glycoprotein
proteolytic modification
-
the soluble form present in maternal serum is converted from the membrane-bound form in placenta by an enzyme with metalloprotease activity by posttranslational proteolytic cleavage between Phe154 and Ala155
side-chain modification
top print hide
TEMPERATURE STABILITY
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
55
-
15 min, form I: about 20% loss, form II: about 70% loss of activity
60
-
30 min, 40-50% loss of activity, SP I, SP II, 15 min, 80% loss of activity
top print hide
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
freeze-thawing, stable
-
lyophilization, stable
-
top print hide
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
-15°C, 0.01 M potassium phosphate, pH 7.4, protein concentration 0.5 mg/ml, 6 months
-
top print hide
Purification/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli
-
two forms, CAP-I and CAP-II
-
top print hide
Cloned/COMMENTARY
ORGANISM
UNIPROT
LITERATURE
expressed in CHO-K1 cells and HEK-293 cells
-
expressed in Sf9 cells using the baculovirus system
expression in 3T3-L1 cell
-
expression in A-MEC cell
-
expression in Escherichia coli
-
expression in HEK-293 cell
expression in HEK-293T cell
-
expression in HEK293 cells
-
leucine aminopeptidase/oxytocinase, expression in Chinese hamster ovary cells
-
top print hide
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
expression is higher in lactating rats
top print hide
ENGINEERING
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
E431A
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
E431D
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
E465D
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
E465Q
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
E487D
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
E487Q
-
inactive mutant enzyme
G428A
-
the ratio of maximal velocity to Km-value is 90% of the value for the wild-type enzyme
G428D
-
80% of wild-type activity with L-Arg-vasopressin, no activity with L-Leu-enkephalin
G428E
-
50% of wild-type activity with L-Arg-vasopressin, no activity with L-Leu-enkephalin
G428Q
-
more than wild-type activity with L-Arg-vasopressin, less than 10% of wild-type activity with L-Leu-enkephalin
H464Y
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
H468Y
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
M430E
-
strong decrease in aminopeptidase activity towards Leu-4-nitroanilide
M430I
-
the ratio of maximal velocity to Km-value is 6.2% of the value for the wild-type enzyme
M430K
-
the ratio of maximal velocity to Km-value is 3.3% of the value for the wild-type enzyme
N432A
-
no activity with L-Arg-vasopressin, or L-Leu-enkephalin
L53A/L54A
-
no change in intracellular trafficking
L76A/L77A
-
mutation results in rapid default of the enzyme to the cell surface. In presence of a dominant interfering mutant of clathrin adaptor GGA1, insulin-stimulated translocation of wild-type enzyme, but not of mutant L76A/L77A is inhibited
additional information
top print hide
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine
top
top
top